<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666442</url>
  </required_header>
  <id_info>
    <org_study_id>RC-CT-2018</org_study_id>
    <nct_id>NCT03666442</nct_id>
  </id_info>
  <brief_title>Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer</brief_title>
  <official_title>Early Evaluation of Chemosensitivity for Low-risk Stage II/III Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemosensitivity of rectal cancer is not discussed clearly. With previous study, the
      investigators design this phase II trial to explore the effect of 2 cycles Xelox
      chemotherapy,so as to explore the early detection of sensitivity of tumor. With inclusion of
      early,intermediate,and bad stage II/III rectal cancer patients, four cycle of Xelox
      chemotherapy was given. After the second cycle, MRI,TRUS,DE,endoscopy,and blood DNA test was
      down to compare with these characteristics of four cycles.so that to detect the data about
      the chemosensitivity of tumor in the early stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemosensitivity of rectal cancer is not discussed clearly. With previous study, the
      investigators design this phase II trial to explore the effect of 2 cycles Xelox
      chemotherapy,so as to explore the early detection of sensitivity of tumor. With inclusion of
      early,intermediate,and bad stage II/III rectal cancer patients, four cycle of Xelox
      chemotherapy was given. After the second cycle, MRI,TRUS,DE,endoscopy,and blood DNA test was
      down to compare with these characteristics of four cycles.so that to detect the data about
      the chemosensitivity of tumor in the early stage.In future, a phase III trial that explore
      the effect of radiation or surgery in these chemoresistant patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>a group of patients receive 4 cycle of Xelox chemotherapy, MRI,TRUS, DE,endoscopy, blood DNA test,before, between and after chemotherapy was compared to detect the effect of chemotherapy in 2 cycles.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor volume</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 3 weeks)</time_frame>
    <description>tumor volume measured by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tumor area in endoscopy</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 3 weeks)</time_frame>
    <description>tumor area measured in endoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tumor volume</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 3 weeks)</time_frame>
    <description>tumor volume measured by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tumor area in endoscopy</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 3 weeks)</time_frame>
    <description>tumor area measured in endoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood DNA test</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 3 weeks)</time_frame>
    <description>blood DNA test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood DNA test</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 3 weeks)</time_frame>
    <description>blood DNA test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor thickness in TRUS</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 3 weeks)</time_frame>
    <description>tumor thickness in TRUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor thickness in TRUS</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 3 weeks)</time_frame>
    <description>tumor thickness in TRUS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive 4 cycles of Xelox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks</description>
    <arm_group_label>chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. .endoscopy and biopsy verified rectal cancer within 12cm from anal verge;

          2. .primary MRI, TRUS, abdomino-chest CT diagnosed early or intermediate or bad Stage
             II/III rectal cancer;

          3. .age from 20-75;

          4. .with informed consent;

        Exclusion Criteria:

          1. .refuse the further treatment after recruiting;

          2. .diagnosis of peritoneal metastasis in the surgery;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziqiang Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziqiang wang, MD</last_name>
    <phone>+8618980602028</phone>
    <email>wangtrial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangbing Deng, MD</last_name>
    <phone>+8618190908162</phone>
    <email>xiangbingdeng@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guoxue Road 37#,West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziqiang Wang, MD</last_name>
      <phone>18980602028</phone>
      <email>wangtrial@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf</url>
    <description>NCCN guideline</description>
  </link>
  <reference>
    <citation>Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13.</citation>
    <PMID>24419115</PMID>
  </reference>
  <results_reference>
    <citation>Sclafani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncol. 2014 Nov;10(14):2243-57. doi: 10.2217/fon.14.127. Review.</citation>
    <PMID>25471037</PMID>
  </results_reference>
  <results_reference>
    <citation>Birlik B, Obuz F, Elibol FD, Celik AO, Sokmen S, Terzi C, Sagol O, Sarioglu S, Gorken I, Oztop I. Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Magn Reson Imaging. 2015 Feb;33(2):201-12. doi: 10.1016/j.mri.2014.08.041. Epub 2014 Nov 13.</citation>
    <PMID>25460330</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang J, Cai Y, Hu H, Lan P, Wang L, Huang M, Kang L, Wu X, Wang H, Ling J, Xiao J, Wang J, Deng Y. Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study. Oncotarget. 2016 Jan 26;7(4):5053-62. doi: 10.18632/oncotarget.6469.</citation>
    <PMID>26646794</PMID>
  </results_reference>
  <results_reference>
    <citation>Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hisada M, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Shiokawa H, Ogawa S, Itabashi M, Kameoka S. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. Cancer Chemother Pharmacol. 2017 Mar;79(3):519-525. doi: 10.1007/s00280-017-3243-7. Epub 2017 Feb 1.</citation>
    <PMID>28150022</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017 Feb 1;28(2):344-353. doi: 10.1093/annonc/mdw616.</citation>
    <PMID>28426108</PMID>
  </results_reference>
  <results_reference>
    <citation>Chee CG, Kim YH, Lee KH, Lee YJ, Park JH, Lee HS, Ahn S, Kim B. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis. PLoS One. 2017 Aug 10;12(8):e0182883. doi: 10.1371/journal.pone.0182883. eCollection 2017.</citation>
    <PMID>28797063</PMID>
  </results_reference>
  <results_reference>
    <citation>Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, Strassburg J, Quirke P, Tekkis P, Pedersen BG, Gudgeon M, Heald B, Brown G; MERCURY II Study Group. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg. 2016 Apr;263(4):751-60. doi: 10.1097/SLA.0000000000001193.</citation>
    <PMID>25822672</PMID>
  </results_reference>
  <results_reference>
    <citation>Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263. Ann Oncol. 2018 Oct;29 Suppl 4:iv263.</citation>
    <PMID>28881920</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Ziqiang Wang,MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer；</keyword>
  <keyword>neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

